Esaote’s E-Scan gets final FDA nod

Article

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when Genoa-based Esaote made what the FDA considered significant changes in the unit’s gradient system during the final development stage.

E-Scan is an open-style MRI scanner dedicated to orthopedic studies, and includes a swiveling patient table between 0.2-tesla permanent magnets. Esaote supplies the unit to U.S. marketing partners Lunar of Madison, WI, and Siemens Medical Systems of Iselin, NJ (SCAN Special Report 1/99).

The agency’s request for a second 510(k) application for E-Scan came as a surprise, according to Lunar, and delayed the product’s launch. Esaote had planned to ship the units in the first quarter of 1999, but since the second 510(k) application was submitted on March 23 and cleared on May 27, the company’s commercialization calendar was interrupted. Although a Lunar spokesperson downplayed the effect of the delay, Lunar’s third quarter fiscal 1999 (end-March) results took a hit when the company couldn’t recognize revenue for $2.7 million in E-Scan orders (SCAN 4/28/99).

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.